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Steroid receptor drugs have been available for more
than half a century, but details of the ligand binding
mechanism have remained elusive. We solved X-ray
structures of the glucocorticoid and mineralocorti-
coid receptors to identify a conserved plasticity at
the helix 6–7 region that extends the ligand binding
pocket toward the receptor surface. Since none of
the endogenous ligands exploit this region, we hy-
pothesized that it constitutes an integral part of the
binding event. Extensive all-atom unbiased ligand
exit and entrance simulations corroborate a ligand
binding pathway that gives the observed structural
plasticity a key functional role. Kinetic measurements
reveal that the receptor residence timecorrelateswith
structural rearrangements observed in both struc-
tures and simulations. Ultimately, our findings reveal
why nature has conserved the capacity to open up
this region, and highlight how differences in the de-
tails of the ligand entry process result in differential
evolutionary constraints across the steroid receptors.
INTRODUCTION
Biological functions originate from, and are maintained by, a
combination of genomic drift and selection. The traditional
method to derive evolutionary relationships is to compare pri-
mary sequences, tertiary structures, and protein function. How-
ever, while changes in the amino acid sequence and placement
of key residues provide useful insights into lineage, this only pro-
vides the basic framework for mechanistic detail. A more com-
plete functional understanding requires protein plasticity to be
considered. Moreover, comparing protein flexibility of related
systems adds an important dimension when exploring evolu-
tionary trajectories (Bhabha et al., 2013).2280 Structure 23, 2280–2290, December 1, 2015 ª2015 Elsevier LtdThe steroid receptor family consists of five closely related re-
ceptors: the mineralocorticoid receptor (MR), the glucocorticoid
receptor (GR), the androgen receptor (AR), the progesterone re-
ceptor (PR), and the estrogen receptors (ERa and ERb) (Fig-
ure 1A). All these receptors bind cholesterol derivatives and
play a critical role in fundamental biological processes, ranging
from pregnancy to early development, the stress response, and
electrolyte homeostasis (Evans, 1988; Mangelsdorf et al., 1995).
Continual pharmaceutical efforts have resulted in several effica-
cious drugs across the family (Cole, 2006; Gravez et al., 2013;
Shelley et al., 2008; Sitruk-Ware and Nath, 2010; Alexander
et al., 2013). However, target class-related side effects limit
the prescription of these drugs for many indications, and the
scope for further improvement is considered to be high (Bertoc-
chio et al., 2011). The receptors share a common architecture
with three separate domains: the N-terminal domain (NTD),
the DNA binding domain, and the ligand binding domain
(LBD). Besides recognizing the ligand pharmacophore, the
LBD also contains the activation function 2 (AF-2), which is
important for transmitting ligand binding information and
partially driving the co-regulator interaction fingerprint (Grone-
meyer et al., 2004). In the resting state, the receptors are asso-
ciated with chaperone proteins in the cytoplasm. Ligand activa-
tion leads to a partial release of chaperone proteins, followed
almost always by nuclear translocation. In the nucleus, the re-
ceptors dimerize and form ligand and context-specific protein
complexes, resulting in activation and/or repression of gene
transcription.
All steroid receptor LBD structures exhibit the typical three-
layered a-helical fold that fully encloses the various compounds
in the ligand binding pocket (Bledsoe et al., 2002; Williams and
Sigler, 1998; Fagart et al., 2005; Matias et al., 2000) (Figure 1B).
When overlaying the steroid receptors, the largest structural
difference in proximity to the ligand is located in the region
where helices 3, 7, and 11 meet (Li et al., 2005). Figure 1C
shows a detailed comparison of GR with its paralog MR. An out-
ward tilt of the helix 6–7 (H6-H7) interface in GR results in an
expanded ligand binding pocket, and the most potent GR li-
gands contain large substituents extending in this directionAll rights reserved
Figure 1. Evolutionary Relationship of the
Steroid Receptors with Structural Compari-
son of GR- and MR-LBD
(A) Evolutionary relationship of the steroid hormone
receptors (ERa, ERb, MR, GR, PR, and AR). Decimal
numbers = distance; integers = bootstrap value.
(B) GR (yellow) in complex with dexamethasone
(magenta) overlaid on MR (light blue) in complex
with dexamethasone (magenta). The AF-2 surface is
located where helices 3, 4, and 12 meet.
(C) Details near the region where helices 3, 7, and 11
meet.
(D) The chemical structures of dexamethasone and
dibC. The steroidal A, B, C, and D rings and posi-
tions 3 and 17 are marked on the dexamethasone
structure.(17a). Despite the smaller pocket in MR, several ligands with
bulky 17a substituents on the steroidal D-ring, such as desisobu-
tyrylciclesonide (dibC, the active metabolite of the prodrug
ciclesonide), are more potent in the MR binding assay than the
endogenous agonist aldosterone.
Plasticity in the H6-H7 region has been reported for ERa, AR,
and PR (Andrieu et al., 2015; Nettles et al., 2007; Kohn et al.,
2012), and appears to be a conserved feature across the nuclear
receptor superfamily (Soisson et al., 2008; Hughes et al., 2012).
To build a detailed understanding for how the differences in re-
ceptor design influence the H6-H7 rearrangements, we deter-
mined the X-ray structures of both MR and GR in complex with
dexamethasone and dibC (Figure 1D). The structures revealed
that when binding a ligand with a large 17a substituent, MR is
fully capable of adopting an open structural conformation, and
that the nature of these rearrangements is clearly distinct from
analogous changes in GR.Why has nature preserved the capac-
ity to open up this region across the steroid receptor family, even
though it is not exploited by the endogenous ligands? Our hy-
pothesis is that the observed plasticity is an integral part of the
ligand entry mechanism.
To test this hypothesis, we performed comprehensive all-atom
unbiased simulations. In these studies, we linked the observed
plasticity in the H6-H7 region to the ligand binding mechanism.
While the simulations clearly identified a common binding
trajectory for the two receptors, they also highlighted detailed
differences in the entry and exit processes. By employing
surface plasmon resonance (SPR) and single-molecule micro-
scopy (SMM), we showed that these differences correlate with
distinct ligand-receptor residence times. Finally, we performed
a bioinformatics analysis whereby we confirmed that GR has
relaxed evolutionary constraints on the H6-H7 amino acid
sequence relative all other steroid receptors. The link to the
ligand binding utility provides a functional understanding for
these observations.Structure 23, 2280–2290, December 1, 2015RESULTS
A Conserved Plasticity
Dexamethasone was originally developed
as a GR-specific agonist (Alexander
et al., 2013) and was used to determine
the first GR-LBD structure (Bledsoe et al.,2002). However, dexamethasone was later shown to also be a
potent MR ligand in a functional reporter gene assay (Rupprecht
et al., 1993). The X-ray structure of MR in complex with dexa-
methasone (MR:Dexa, Figure 2A) is similar to the corresponding
GR:Dexa structure (normalized root-mean-square deviation
[RMSD] of 0.37 A˚ for 100 Ca atoms) (Table 1). However, exam-
ining the region where helices 3, 7, and 11 meet confirms that
the 17a subpocket is considerably smaller in the MR structure
than in the GR structure (Figure 1C). This is reflected in the total
volume of the MR:Dexa ligand binding pocket, which is approx-
imately 543 A˚3 compared with 572 A˚3 in the GR:Dexa structure
(Figure S1).
It has been proposed that structural differences in the loop
between helices 6 and 7 are primarily due to replacement of
Ser843MR by Pro637GR, which alters the geometrical constraints
of this region and allows GR to adopt a more open conformation
(Li et al., 2005). However, despite the limited size of the MR sub-
pocket, dibC has higher affinity than aldosterone in the scintilla-
tion proximity assay using tritiated aldosterone and MR-LBD
fusion protein (Ki for dibC is 0.18 nM compared with 1.0 nM for
aldosterone, Figure S2). To study the structural flexibility associ-
ated with large 17a substituents, we determined the complex
structures of MR:dibC and GR:dibC (Table 1).
The structure of MR:dibC superimposes well on the MR:Dexa
structure (normalized RMSD 0.28 A˚ for 100 Ca atoms). dibC is
placed in a nearly identical position as dexamethasone in the
binding pocket, with all polar interactions conserved (Figure 2B).
In addition, the AF-2 surface remains virtually unchanged, with
key interactions to the NCOA1 peptide intact. However, while
these two receptor conformations are closely related, dibC in-
duces a large rearrangement of the H6-H7 loop region, essen-
tially extending the ligand binding pocket toward the receptor
surface (Figure 3A). Specifically, side chains of Ser843MR,
Met845MR, and Cys849MR in the MR:Dexa complex occupy
the same volume as the cyclohexyl motif of dibC, forcing theª2015 Elsevier Ltd All rights reserved 2281
Figure 2. Comparison of the Complex Structures of MR:Dexa and
MR:dibC
(A) Stereo view of the 2mFo-dFc density map of the MR:Dexa ligand binding
pocket.
(B) The structure of MR (light blue) in complex with dexamethasone (magenta)
superimposed on MR (dark blue) in complex with dibC (white). The steroid
template overlays nearly perfectly (RMSD 0.28 A˚) with all hydrophilic in-
teractions conserved.receptor to adopt a new conformation (Figure 3B). This leads to
a repositioning of helix 6 and an extension of helix 7. While
Ser843MR was previously buried within the protein and
engaged in a hydrogen bond to the backbone nitrogen of
Met845MR, it is now exposed to the solvent, forming the new
start of helix 7 (Figure 3A). Recent data suggest that phosphor-
ylation of this residue affects both ligand binding and receptor
translocation into the nucleus (Shibata et al., 2013). The
structural changes observed here explain how the receptor
may use the local plasticity to make Ser843MR available for
modification.
The size of the 17a pocket in the MR:dibC complex increases
significantly (total ligand binding pocket volume 714 A˚3, Fig-
ure S1), and the superposition on the GR:Dexa structure shows
that this region now adopts a more closely related structural
state (Figure 3C). Finally, while GR in complex with dibC (Fig-
ure 3D) expands the 17a pocket (total ligand binding pocket vol-
ume 661 A˚3, Figure S1) relative to the GR:Dexa structure, it does
not alter any of the secondary structural elements. Instead, the
H6-H7 region appears to be shifted in a rigid way in response
to cyclohexyl of dibC. While plasticity in the H6-H7 region seems2282 Structure 23, 2280–2290, December 1, 2015 ª2015 Elsevier Ltdto be conserved across these two receptors, the details of the
ligand-driven rearrangements are different.
To quantify the flexibility in the H6-H7 region across the steroid
receptor family, we performed principal component analysis for
all X-ray structures from the PDB for each receptor. This allows
visualization of the variance between structures as a set of
normal modes. While the description of this variance will be
highly dependent on what regions of the binding pocket are ex-
ploited by the various ligands, the mode describing H6-H7 mo-
tion is one of the strong features (Figure S3). However, for MR
the H6-H7 motion is only prominent if we include the MR:dibC
structure from this work, emphasizing that theMR:dibC structure
describes a novel structural conformation.
Modeling Nonbiased Entry and Exit Pathways
Spontaneous ligand binding events have been investigated us-
ing molecular dynamics in both exposed (Buch et al., 2011)
and partially exposed binding sites (Dror et al., 2011). However,
nuclear receptors have fully occluded binding pockets that likely
require significant rearrangements for ligand entry. Therefore,
we decided to use protein energy landscape exploration
(PELE) (Borrelli et al., 2005), an alternative approach that uses
Monte Carlo algorithms with structural prediction for efficient
sampling of the protein-ligand energy landscape. For ligand
escape simulations, the MR and GR X-ray complex structures
were used as the starting position. For ligand binding studies,
the ligand was randomly placed in the bulk solvent and allowed
to freely migrate. All simulations were completed in the presence
and absence of a co-factor peptide at the AF-2 site (NCOA1 res-
idues 1,430–1,441 forMR andNCOA2 residues 741–753 for GR).
In addition, both the wild-type protein sequences and the spe-
cific mutants present in the X-ray structures were used.
Ligand Dissociation
For all permutations of both MR and GR, we performed three
separate exit simulations, observing only one exit trajectory
perforating the surfacewhere helices 3, 7, and 11meet. Figure 4A
illustrates the MR:Dexa exit pathway simulation with the array of
dexamethasone positions superimposed on the initial MR struc-
ture. Notably, ligand motion is coupled with significant rear-
rangement of the protein backbone along themigration pathway.
In particular, the loop connecting helices 6 and 7 is shifted out-
ward to accommodate ligand release (Figure 4B). Interestingly,
the simulated protein movements mimic the differences be-
tween the MR:Dexa and MR:dibC structures shown in light and
dark blue, respectively. Root-mean-square fluctuations (RMSF)
along the exit trajectory (Figure 4C) clearly show that the move-
ments of the H6-H7 region are considerably larger than for the
rest of the protein.
Figure 5 shows the corresponding simulation for GR:Dexa
(equivalent simulations for MR:dibC and GR:dibC resulted in
the same exit trajectory). Based on the complete set of ligand
dissociation simulations it is apparent that both MR and GR
have the same ligand unbinding pathway. In addition, while
ligand exit is associated with similar protein motions, the fluctu-
ations in the H6-H7 region are significantly larger for MR than for
GR (Figure 5C). This is in agreement with the idea that GR would
require smaller rearrangements, because the receptor is more
open to begin with.All rights reserved
Table 1. Data Collection and Refinement Statistics
MR:Dexa MR:dibC GR:Dexa GR:dibC
Data Collectiona
PDB ID 4UDA 4UDB 4UDC 4UDD
Space group P212121 P41212 P3221 P3221
a, b, c (A˚) 73.00, 81.40, 45.23 75.92, 75.92, 117.00 84.66, 84.66, 105.91 87.20, 87.20, 102.89
a, b, g () 90.00, 90.00, 90.00 90.00, 90.00, 90.00 90.00, 90.00, 120.00 90.00, 90.00, 120.00
Resolution (A˚) 40.7–2.03 (2.17–2.03) 48.79–2.36 (2.55–2.36) 31.81–2.50 (2.67–2.50) 40.14–1.80 (1.85–1.80)
Rsym (Rmerge) 0.06 (0.50) 0.13 (1.30) 0.08 (0.55) 0.08 (1.05)
I/sI 13.10 (2.30) 15.10 (1.90) 8.80 (1.60) 7.40 (0.70)
Completeness (%) 83.9 (83.7) 100.0 (100.0) 99.6 (99.5) 99.9 (100.0)
Redundancy 3.3 (2.5) 12.6 (11.7) 4.1 (4.2) 3.5 (3.6)
Refinement
Resolution (A˚) 2.03 2.36 2.50 1.80
No. of reflections 15,085 14,672 15,559 42,339
Rwork/Rfree 0.185/0.240 0.182/0.218 0.210/0.253 0.213/0.224
No. of atoms
Protein 2,080 2,118 2,133 2,184
Ligand/ion 34 49 64 146
Water 101 60 83 250
B factors
Protein 30.14 53.25 49.72 33.25
Ligand/ion 22.12 44.16 34.51 23.55
Water 36.03 56.86 46.23 46.95
RMSD
Bond lengths (A˚) 0.010 0.010 0.010 0.010
Bond angles () 1.01 1.04 1.12 1.06
MolProbity score
Clashscore 2 1 1 1
Ramachandran outliers (%) 0 0 0.4 0
Side-chain outliers (%) 1.7 1.7 2.5 0.8
aValues in parentheses represent highest-resolution shell.Ligand Association
To investigate ligand entry, we randomly placed dexamethasone
in the bulk solvent and released it to freely probe the protein sur-
face. For each receptor we performed five runs with 64 indepen-
dent trajectories over 48 hr. Each run yielded one to two trajec-
tories whereby the ligand entered the binding pocket. In all runs
the ligand is free tomovewithout anypredefined searchdirection.
Figure 6A shows the evolution of the ligand heavy atom RMSD
to the crystallographic complex for one of theMR:Dexa runs. It is
clear that most of the trajectories explore the receptor surface
with some excursions into the bulk solvent. However, the blue
and red trajectories enter the ligand binding pocket at steps
50 and 210, respectively. While the entry along the blue tra-
jectory is relatively fast, the red demonstrates the unbiased
nature of the simulation, probing a large portion of the receptor
surface before finding the entrance pathway. Figure 6B shows
representative ligand centers of mass along these trajectories
superimposed on the initial protein structure, with the entry to
the binding pocket denoted by a surface representation. The
corresponding ligand entry simulation for GR is shown in Fig-
ure S4. In keeping with the ligand escape simulations for allStructure 23, 2280–22runs in both systems, trajectories entering the ligand binding
pocket pierce the protein surface at the H3-H7-H11 junction.
The MR:Dexa binding event is demonstrated in greater detail in
the Movie S1.
While the mutants used in the X-ray structures did not influ-
ence the simulations significantly, removal of co-factor peptide
at the AF-2 resulted in larger fluctuations in both helix 12 and
the H3-H7-H11 junction along the exit and entrance trajectories.
However, the ligand entry pathway remained unchanged. The
presence of co-regulator peptide has been shown to affect the
ligand binding kinetics (Pfaff and Fletterick, 2010).
Active-Site Ligand Refinement and Binding Free Energy
Once the entrance path to the MR binding pocket had been
located, we refined the free search with local enhanced sampling
to obtain a precise pose for the best binder. This procedure does
not add any bias in the ligand search direction, but limits the
sampling to the region around the entrance point (typically 10–
15 A˚). Figure 7A shows the interaction energy profile plotted
against the ligand heavy atom RMSD to the crystallographic
complex for the MR:Dexa refining process (400 trajectories).90, December 1, 2015 ª2015 Elsevier Ltd All rights reserved 2283
Figure 3. Comparison of the Complex Struc-
tures of MR:Dexa, MR:dibC, GR:Dexa, and
GR:dibC
(A) MR (light blue) in complex with dexamethasone
(magenta) overlaid on MR (dark blue) in complex
with dibC (white).
(B) The cyclohexyl motif of dibC comes into direct
conflict with residues from H7 (MR:Dexa), enforcing
a new structural state.
(C) MR (dark blue) in complex with dibC (white)
superimposed on GR (yellow) in complex with
dexamethasone (magenta).
(D) GR (yellow) in complex with dexamethasone
(magenta) overlaid on GR (orange) in complex with
dibC (white).The lowest binding energies are derived from poses located
within 0.75 A˚ RMSD of the X-ray ligand conformation. The sam-
pling places dexamethasone in the accurate orientation with the
A-ring 3-keto moiety pointing toward the Arg817MR-Gln776MR
pair from helices 5 and 3, and the D-ring hydroxyacetyl ap-
proaching the Asn770MR on the N-terminal half of helix 3 (Fig-
ure 7B). Studying the protein-ligand interaction energy plot in
more detail (Figure 7A), it is interesting that the surface explora-
tion exhibits local minima near RMSDof 12 A˚. In the crystal struc-
ture of GR:Dexa and GR:dibC, this site is occupied by a steroid-
like CHAPS molecule that is part of the protein formulation
(Figure S5). In addition, for MR a nonsteroidal antagonist has
been observed at this position (Hasui et al., 2011). As such, the2284 Structure 23, 2280–2290, December 1, 2015 ª2015 Elsevier Ltd All rights reservedregion may correspond to a peripheral
binding site at the H3-H7-H11 junction,
and the energy barrier located at the 11-
to 12-A˚ segment in Figure 7A reflects the
energy cost associated with the surface-
crossing event through the entry channel.
The fast performance of PELE, together
with the local restriction in the refinementexploration, facilitates running hundreds of trajectories. Based
upon Markov state model (MSM) analysis (Takahashi et al.,
2014), we used these data to calculate the binding free energies
for MR:Dexa and MR:dibC. While absolute values might be
slightly shifted due to the absence of an exhaustive surface/
bulk exploration, relative values should be in reasonable agree-
ment, because both ligands share entry point and binding site.
Figure 7C shows a 2D projection of the potential mean field
(PMF) obtained for MR:Dexa along the 400 refinement trajec-
tories. The red area corresponds to the bulk exploration,
whereas the global minimum, shown in blue, corresponds to
ligand positions matching the experimental structure (Figures
7A and 7B). Integration of the PMF volume at the active site,Figure 4. Ligand Exit Pathway for the
MR:Dexa Complex
(A) The ligand center of mass is highlighted as blue
beads. The ligand atoms are shown as transparent
space fill.
(B) Detail of the backbone rearrangement along the
exit pathway. The MR:Dexa and MR:dibC X-ray
structures are shown in light and dark blue,
respectively, with dexamethasone in the binding
pocket in magenta. Three protein cartoon snap-
shots and one pose of dexamethasone as it passes
through the receptor surface from the exit simula-
tions are shown in green.
(C) Ca RMSF relative the average structure along
the MR:Dexa exit pathway plotted for each residue.
The dotted line denotes the average RMSF across
the LBD. Helices 6 and 7 are marked with green
shading.
Figure 5. Ligand Exit Pathway for the
GR:Dexa Complex
(A) The ligand center of mass is highlighted as blue
beads. The ligand atoms are shown as transparent
space fill.
(B) Detail of the backbone rearrangement along the
exit pathway. The GR:Dexa and GR:dibC X-ray
structures are shown in light yellow and orange,
respectively. Three snapshots from the exit simu-
lations are shown in green, and dexamethasone in
the binding pocket is shown for reference in
magenta.
(C) CaRMSF relative the average structure along the
GR:Dexa exit pathway where helices 6 and 7 are
marked with green shading.where we observe a smooth function (as opposed to the bulk
solvent or entrance pathway), converges to a binding free energy
of 7.5 kcal/mol for dexamethasone and 9.3 kcal/mol for
dibC. The difference in binding free energy of 1.8 kcal/mol is in
quantitative agreement with the experimental difference of
2.09 kcal/mol (derived from theKi values of 6.3 nM for dexameth-
asone and 0.18 nM for dibC).
Residence Time Measurements
The ligand entry and exit mechanism establishes a functional
role for helices 6 and 7 as a gatekeeper. In addition, the simula-
tions revealed that the structural rearrangements required for
ligand entry and exit are significantly different for GR and MR.
As a consequence, the ligand binding kinetics should differ for
the two receptors. Using both SPR and SMM (Gunnarsson
et al., 2015), we measured the residence time of both dexameth-
asone and dibC by monitoring the time-resolved change in re-
ceptor binding to a surface-immobilized co-regulator peptide
upon addition of >10-fold concentration excess of a reference
compound (Figure S6). The data from all experiments are sum-
marized in Table 2. In all instances, koff is larger for GR than for
MR, hence the residence time is longer in MR. This is in agree-Structure 23, 2280–2290, December 1, 2015ment with the observations that MR
requires a larger rearrangement of the
H6-H7 region compared with GR (Figures
4 and 5). In addition, dexamethasone has
a larger koff than dibC, reflecting the factthat dibC is a bulkier ligand. Finally, while the different measure-
mentmethods result in the same pattern for bothGR andMRand
dexamethasone and dibC, providing confidence to the analysis,
the systematically larger off rates using SMM likely reflect the
temperature difference at which the experiments were conduct-
ed (20C for SMM and 10C for SPR).
Differential Selection Pressure
Studies on the evolution of GR from the ancestral corticoid re-
ceptor revealed that GR has accumulated a number of mutations
on and in the proximity of helix 7 that prevents reversal of evolu-
tion (Bridgham et al., 2009). As our findings suggest that there is
an intimate link to the ligand binding function, we decided to
investigate the evolutionary consequences across thewhole ste-
roid receptor family. To explore this, sequence clusters for each
receptor were downloaded from OrthoDB (Waterhouse et al.,
2013). The sequences for each receptor were aligned using
ClustalX version 2.0 (Larkin et al., 2007) and the pairwise species
overlap with GR was selected for each receptor. Each residue
position was then assigned a variability score based on the num-
ber of different amino acids at that position across the various
species. All receptor sequences were overlaid on the GRFigure 6. Unbiased Simulation of Dexa-
methasone Entering the MR Binding Pocket
(A) Each line represents the ligand heavy atom
RMSD to the ligand from the crystallographic
structure for a single trajectory. Two of the trajec-
tories represented by blue and red lines enter the
ligand binding pocket at steps 52 and 214,
respectively.
(B) The ligand center of mass for the two trajec-
tories that enter the binding pocket are shown as
blue and red spheres. The region where the ligands
enter the binding pocket is emphasized as a sur-
face with two ligands from the simulations shown in
full stick representation.
ª2015 Elsevier Ltd All rights reserved 2285
Figure 7. Refined Ligand Binding Simulations and Estimated Bind-
ing Free Energy
(A) The protein-ligand interaction energy plotted against the ligand heavy atom
RMSD to the crystallographic structure along the 400 refinement trajectories in
MR:Dexa.
(B) MR (blue) in complex with dexamethasone (magenta) overlaid on the lowest
interaction energy structure after the refined exploration (green).
(C) X-Z 2D projection of the PMF obtained in the MSM analysis for the same
process.
Table 2. Measurement of koff Using SPR and SMM
Ligand (Method) GR (s1) MR (s1)
Dexa (SPR, 10C) 0.0034 0.0011
dibC (SPR, 10C) 0.0010 <0.0001
Dexa (SMM, 20C) 0.0070 0.0025
dibC (SMM, 20C) 0.0029 0.0012sequence using X-ray structures to define the equivalent posi-
tions. Finally, we plotted the variability score against the amino
acid sequence for all receptor pairs (Figure 8). The data confirm
that important structural elements of the receptors are relatively
conserved. For example, the variability score for the AF-2 sur-
face (the N-terminal end of H12, H4, and the C-terminal end of
H3), which is directly involved in the protein-protein interaction
transmitting the ligand activation signal, is consistently low for
all receptors. However, H6-H7 exhibits a greater variability score
in GR relative to all other receptors. Interestingly, GR also has a
segment of higher variability near the C-terminal end of H11. This
region sits directly across from the N-terminal end of H7 (Fig-
ure 1C), and it is conceivable that amino acid sequences of these
regions may well co-vary with each other. Figure S7A shows the
variability score for the individual amino acids in the H6-H7 re-
gion for the full set of GR species. It is clear that the high vari-
ability score of the region resides in discrete positions (primarily
in residues 631, 632, 635, 638, and 640). These residues are all
located on the outside of the receptor in both the GR:Dexa and
GR:dibC structures (Figure S7B).
DISCUSSION
The fundamental role and mechanism of action of steroid recep-
tors have been studied extensively, yet details of the ligand bind-2286 Structure 23, 2280–2290, December 1, 2015 ª2015 Elsevier Ltding mechanisms have remained unclear. By comparing the
structures of MR and GR in complex with dexamethasone and
dibC, we confirmed the intrinsic capacity to open up the H6-
H7 region. While the GR:Dexa structure adopts an open confor-
mation compared with the MR:Dexa complex, the MR:dibC
structure is able to extend the ligand binding pocket significantly
and adopt a structural state akin to the GR:Dexa arrangement.
Studies of ancestral corticoid receptor (AncCR), the common
predecessor of MR and GR, revealed that the Ser106AncCR (cor-
responding to Ser843MR) to Pro637GR switch was a permissive
mutation that facilitated a subsequent Leu111AncCR (corre-
sponding to Leu848MR) to Gln642GR mutation (Bridgham et al.,
2006). This is an example of conformational epistasis and has
played an important role in the evolution of GR hormone selec-
tivity (Ortlund et al., 2007). We show that GR and MR demon-
strate a similar capacity to form an open conformation, and it
is likely that the AncCR also exhibited the same flexibility. Hence,
as GR evolved from AncCR, the Ser106AncCR to Pro637GR muta-
tion would primarily serve to select a subset of preexisting struc-
tural states, rather than creating a completely new arrangement.
The importance of conformational selection over induced fit has
provided mechanistic insights for several biological systems
(Changeux, 2013), and it is plausible that evolution through mu-
tation often operates in an analogous way.
Extensive ligand binding simulations revealed that the entry
and exit trajectories all pass through the H3-H7-H11 junction.
As the ligands cross the receptor surface, the outward bending
motion of theH6-H7 region is qualitatively similar to the observed
perturbations caused by the large 17a cyclohexyl substituent in
the dibC complex structures, linking the observed H6-H7 plas-
ticity to the ligand binding mechanism. Interestingly, H7 has
also been shown to be important for dimerization of several nu-
clear receptors (Osz et al., 2012). This suggests that the two
functions could be linked for these receptors, but the strength
of this relationship remains to be determined. The results from
the ligand binding simulations indicate that large-amplitude pro-
tein motions of helix 12, as suggested by apo and holo crystallo-
graphic nuclear hormone receptors (Moras and Gronemeyer,
1998; Yen, 2001; Brzozowski et al., 1997), are not required for
ligand entry. Instead, the conformation of the LBD is likely to
resemble the ligand bound agonistic conformations of the recep-
tors during the ligand entry step (Capelli et al., 2013; Batista and
Martı´nez, 2013). We show that small-scale vibrations combined
with a structural rearrangement of H6-H7 region are enough to
identify an energetically favorable pathway to allow the ligands
to diffuse into the binding pocket. In contrast to other modeling
studies using biased protocols, we do not observe multiple
ligand entry or exit pathways (Capelli et al., 2013; Sonoda
et al., 2008; Aci-Se`che et al., 2011). Finally, careful analysis
of the binding energies along the entry trajectory revealed aAll rights reserved
Figure 8. Evolutionary Conservation of the
LBD for the Steroid Receptors
The graphs show normalized amino acid variability
score for pairwise comparisons of MR (A), PR (B),
AR (C), ERa (D), and ERb (E) in blue versus GR in
red plotted against the GR amino acid sequence.
The variability score was average normalized and
smoothed using a five-amino-acid sliding window.
Helices 1–12 are annotated using vertical bars
(green: H6–7; blue: H10–11; gray: all others). High
variability scores indicate less conservation.potential peripheral binding site. While it requires further charac-
terization, the function of such a site on the surface of the recep-
tor could serve to capture the ligands and increase the chances
for productive binding events.
It is firmly established that steroid receptors depend on a num-
ber of chaperone and co-chaperone proteins for correct folding
that is capable of high-affinity hormone binding (Grad and Pic-
ard, 2007). Although the ligand entry function is likely to have
evolved before the synergies with chaperone proteins, these
proteins will nevertheless limit the access to the receptors and
thereby form boundary conditions for any ligand entry hypothe-
sis. Mutation and peptide competition studies suggest that
Hsp90 interacts at the AF-2 surface (Ricketson et al., 2007;
Fang et al., 2006). In addition, co-chaperones have been map-
ped to interact with regions surrounding the C-terminal end of
H1 and the N-terminal end of H3 (Caaman˜o et al., 1998), and
with the loop that connects them (Cluning et al., 2013). Neither
of these areas overlap with the entry site proposed here. Howev-
er, previous studies have shown that the chaperone complex
promotes the ligand binding process (Grad and Picard, 2007).
Interestingly, the simulations whereby we removed the co-regu-
lator peptides resulted in greater fluctuations in both the H3-H7-
H11 junction and H12. These results suggest that the presence
of chaperone proteins at remote sites can allosterically influence
the ligand entry process proposed here.Structure 23, 2280–2290, December 1, 2015While the dibC complex structures
show that both corticoid receptors can
adopt an open conformation, they also
highlight that the plasticity in the H6-H7
region is different. For MR, the challenge
from a large 17a substituent results in a
complete rearrangement of the H6-H7
structure. In contrast, GR responds with
a rigid shift of the region. A closer inspec-
tion of the simulations revealed ensuing
differences as MR require larger rear-
rangements in the gatekeeper residues
for productive ligand binding and unbind-
ing. This is in agreement with the kinetic
measurements revealing that both dexa-
methasone and dibC exhibit longer re-
ceptor residence times in MR than in
GR. However, these observations do not
necessarily result in differences in ligand
affinity per se, as both ligand entry and
exit will be governed by the same plas-ticity, potentially affecting on and off rates equally. Nevertheless,
it is important to note that ligand binding and unbinding are
asymmetric events. While ligand binding occurs with the recep-
tor in the chaperone complex in the cytoplasm, unbinding will
likely occur in the different protein complex. As such, it is
tempting to speculate that the relative stabilization of the open
versus the closed conformation may differ for the two states.
This could increase the apparent ligand affinity and potentially
add another layer of differentiation. To resolve this, detailed
structural information on the relevant protein complexes would
be required.
The distinct receptor blueprints also appear to have evolu-
tionary consequences. By comparing the amino acid sequence
for different species across all steroid receptors, we found that
GR exhibits a higher mutational frequency in the H6-H7 region.
We propose that as GR evolved a cortisol selectivity profile,
the change in the dynamic profile of the H6-H7 region, through
the Ser106AncCR to Pro637GR mutation, altered the boundary
conditions for the ligand entry mechanism. While for MR, resi-
dues need to be compatible with two distinct structural states
during ligand entry, for GR the equivalent residues will be
exposed to the solvent throughout the process. As a result the
selection pressure was relaxed for specific positions in this re-
gion for GR, which explains why subsequent mutations could
build.ª2015 Elsevier Ltd All rights reserved 2287
The tremendous growth in the number of available X-ray struc-
tures from increasingly more advanced protein classes and
complexes provides a plethora of snapshots of molecular mech-
anisms in action. However, to bridge the gap to detailed mecha-
nistic insights and to establish evolutionary relationships, orthog-
onal data from biochemical experiments and in silico modeling
are required. By combining information from several X-ray struc-
tures, extensive simulations, kineticmeasurements, andbioinfor-
matics analyses, we have uncovered the ligand binding mecha-
nism into the occluded binding pocket of steroid hormone
receptors. Ligand binding to the steroid receptors marks the first
step in a chain of events that in the end triggers both broad
genomic and nongenomic mechanisms. Understanding the de-
tails of ligand association and dissociation may facilitate the
rational design of molecules that exploit the plasticity of the entry
and exit processes to a greater extent. This could yield ligands
with differentmodes of action, such as antagonists that block nu-
clear translocation or agonists with extended receptor occu-
pancy and a prolonged pharmacological response.
EXPERIMENTAL PROCEDURES
Protein Expression, Purification, Crystallization, Structure
Determination, and Analyses
The detailed protocols are described in the Supplemental Experimental Proce-
dures. For structure, the following protein constructs were used: GR:Dexa,
GR-LBD (amino acids 500–777) N517D, F602S, C638D; GR:dibC, GR-LBD
(amino acids 500–777) N517D, V571M F602S, C638D; MR:Dexa, MR-LBD
(amino acids 735–984) C808S, C910S; MR:dibC, MR-LBD (amino acids
735–984) C808S, S810L, C910S. For the kinetic measurements, the following
constructs were used: GR, GR-LBD (NR3C1; amino acids 529–777); MR, MR-
LBD (amino acids 712–984) C808S.
Mineralocorticoid Receptor Ligand Competition Binding Assay
A scintillation proximity-based radioligand binding assay was used tomeasure
the ligand displacement of aldosterone to human MR-LDB. The detailed pro-
tocol is presented in the Supplemental Experimental Procedures.
PELE Simulations
Systems Setup
Initial coordinates for GR and MR were obtained from the crystals presented
here. Three different receptor models were prepared: (1) the crystallographic
structures, (2) the wild-type receptors generated by reverting the crystallo-
graphic mutations with the Schro¨dinger package (Schro¨dinger, 2013), and
(3) the wild-type receptors in absence of the peptide co-factor. All structures
were preprocessed with the protein preparation wizard (Madhavi Sastry
et al., 2013) available in the Schro¨dinger package, adding hydrogen atoms
and optimizing the hydrogen bond network, followed by a final visual
inspection.
PELE Sampling
PELE combines a Monte Carlo approach with protein structure prediction
methods, allowing exploration of long-timescale atomic biophysical pro-
cesses (Borrelli et al., 2005; Cossins et al., 2012). Three main steps define
the algorithm: (1) protein backbone and ligand perturbation, (2) specific side-
chain sampling, and (3) global minimization (for more details see, for example,
Kotev et al., 2015). The program uses anOPLS (Optimized Potentials for Liquid
Simulations) all-atom force field with an implicit SGB (surface-generalized
Born) continuum solvent model.
Ligand Exit Simulations
From the crystallographically prepared models, the exit protocol included
random ligand’s translations of 0.8 A˚ and rotation of 0.2 radians. The backbone
perturbation included the lowest six anisotropic network model modes with
maximum displacements of each a carbon up to 1 A˚. A spawning criteria of
4 A˚ was used: any ligand whose center of mass is 4 A˚ behind the structure2288 Structure 23, 2280–2290, December 1, 2015 ª2015 Elsevier Ltdwith the center of mass farthest coordinates (with respect to the initial posi-
tion), in any direction, will abandon its position and continue the execution
with the coordinates from the leading (farthest) one. Thus, all processors
search collectively, with no bias in direction, for an effective escape path. Sim-
ulations were finished after the ligand’s solvent-accessible area was larger
than 0.5, with typical simulations times of 10–20 CPU hr.
Ligand Entrance Simulations
Starting from 20 conformations where the ligand is randomly distributed over
the protein surface, free search simulations were performed with runs of 64 in-
dependent simulations (no spawning criteria were used) for 48 CPU hr. Ligand
perturbation included equally probable translations of 3.0 A˚/1.0 A˚ and rotation
of 0.25/0.05 radians. Ligand displacement direction was randomly updated
every six steps, thus ensuring that trajectories explored the entire surface.
Furthermore, keeping the perturbation direction for six steps is necessary to
observe entrance events in difficult cases.
Residence Time Determination
Residence time measurements of GR/MR:dexamethasone and dibC were
determined using SMM and SPR (Biacore). In brief, GR/MR was preequili-
brated with dexamethasone/dibC. Directly after addition of budesonide/
aldosterone, the rate of receptor binding to the surface-immobilized co-factor
peptide, caused by the ligand-induced change in affinity, was monitored
continuously over 15 min with SMM or by consecutive injection cycles (typi-
cally six) in SPR. See the Supplemental Information for details on surface prep-
aration and experimental procedures. The dissociation rate was determined
by exponential fits to the change in binding rate as a function of time.
Sequence Homology Analysis
Sequence clusters for each receptor were downloaded from the OrthoDB
database (Waterhouse et al., 2013) by searching for the human ENS gene ID
and selecting the vertebrate subset. For each receptor, sequences with a
length two SDs below average length or that contained more than 100 ‘‘X’’ (un-
known amino acids) were removed. The sequences for each receptor were
aligned using ClustalX version 2.0 (Larkin et al., 2007), then further filtered to
only keep sequences with an intact H6-H7 region (maximum 1 indel or ‘‘X’’
and R50% identity to the human H6-H7 region; sequences with large indels
in H6-H7 were removed followed by realignment and refiltering to correct for
alignment errors around indels). The filtered sets were scored using custom
perl scripts; for each position in the alignment, a variability score was calcu-
lated by counting the number of different types of amino acids (i.e. if a position
contained 5F, 3Y, and 9L, then the score is 3). To remove bias stemming from
the inclusion of sequences from different species across the various receptors,
we generated subsets wherein the same species were included for pairs of GR
with either of (MR, PR, AR, ERa, ERb). The paired subsets were realigned for
each receptor, and the resulting alignments were analyzed and scored as pre-
viously described. Finally, the scores were normalized (variability score minus
average variability score for LBD) and smoothed using a sliding window of five
amino acids, and plotted against the GR protein sequence.
Phylogenetic Analysis of the Human LBD Region
Human sequences for the studied nuclear receptors (AR, ERa, ERb, GR, MR,
and PR) were extracted from the aforementioned dataset. Sequences were
trimmed so that only the LBD region remained, aligned using ClustalX, and
manually edited based on the structure (minor adjustments). The tree was
calculated using ClustalX (bootstrap 1,000 iterations) and visualized using
NJplot version 2.3 (Perrie`re and Gouy, 1996).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures and one movie and can be found with this article online at
http://dx.doi.org/10.1016/j.str.2015.09.012.
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